MCID: OCL022
MIFTS: 41

Ocular Melanoma

Categories: Rare diseases, Skin diseases

Aliases & Classifications for Ocular Melanoma

MalaCards integrated aliases for Ocular Melanoma:

Name: Ocular Melanoma 49 51
Malignant Melanoma of Eye 69

Classifications:



External Ids:

UMLS 69 C0558356

Summaries for Ocular Melanoma

NIH Rare Diseases : 49 Ocular melanoma (OM) is a cancer in pigment-producing cells of the eye called melanocytes.   Melanocytes are cells that produce the pigment melanin that colors the skin, hair, and eyes, as well as forms moles.  There are four tissues in the eye in which melanoma can develop: the uveal tract (uvea); conjunctiva; eyelid; and orbit.  The uvea - the middle layer within the eye  - is divided into three main parts: the iris, ciliary body, and choroid.  Uveal melanoma, also called intraocular melanoma, is the most common ocular melanoma. Conjunctival melanoma manifests on the surface of the eye and has been increasing in incidence. Eyelid and primary orbital melanoma are the least common variants. Last updated: 1/14/2013

MalaCards based summary : Ocular Melanoma, also known as malignant melanoma of eye, is related to bap1 tumor predisposition syndrome and melanoma. An important gene associated with Ocular Melanoma is MC1R (Melanocortin 1 Receptor), and among its related pathways/superpathways are NF-kappaB Signaling and Mesenchymal Stem Cell Differentiation Pathways and Lineage-specific Markers. The drugs Dacarbazine and Bevacizumab have been mentioned in the context of this disorder. Affiliated tissues include eye, liver and skin, and related phenotypes are hematopoietic system and endocrine/exocrine gland

Related Diseases for Ocular Melanoma

Diseases related to Ocular Melanoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 53)
# Related Disease Score Top Affiliating Genes
1 bap1 tumor predisposition syndrome 32.0 BAP1 BRCA2
2 melanoma 29.9 BAP1 IL2 KIT MC1R
3 hepatitis 10.3
4 choroiditis 10.2
5 tumor predisposition syndrome 10.2 BAP1 BRCA2
6 peritoneum cancer 10.2 BAP1 BRCA2
7 ocular cancer 10.0 BRCA2 IL2
8 maxillary sinus adenoid cystic carcinoma 10.0 IL2 KIT
9 dysgerminoma of ovary 10.0 BRCA2 KIT
10 ovarian cancer 1 10.0 BRCA2 IL2
11 mucosal melanoma 10.0 IL2 KIT
12 mast cell neoplasm 9.9 IL2 KIT
13 melanoma metastasis 9.9
14 blood group, i system 9.9
15 melanoma, uveal 9.9
16 leukocyte disease 9.9 IL2 KIT
17 toxic shock syndrome 9.9 CIITA IL2
18 combined immunodeficiency, x-linked 9.8 CIITA IL2
19 skin melanoma 9.7
20 lentigines 9.7 KIT MC1R
21 integumentary system cancer 9.6 KIT MC1R
22 leukemia 9.6
23 thyroiditis 9.6
24 mediastinitis 9.6
25 sinusitis 9.6
26 peritonitis 9.6
27 lymphoma 9.6
28 breast cancer 9.6
29 dysplastic nevus syndrome 9.6
30 dry eye syndrome 9.6
31 syncope 9.6
32 retinal detachment 9.6
33 malignant peritoneal mesothelioma 9.6
34 aging 9.6
35 arachnoiditis 9.6
36 endotheliitis 9.6
37 budd-chiari syndrome 9.6
38 panophthalmitis 9.6
39 alpha/beta t-cell lymphopenia with gamma/delta t-cell expansion, severe cytomegalovirus infection, and autoimmunity 9.6
40 peritoneal mesothelioma 9.6
41 microcephaly, epilepsy, and diabetes syndrome 9.6
42 episodic pain syndrome, familial, 1 9.6
43 cervicitis 9.6
44 acute leukemia 9.6
45 liposarcoma 9.6
46 b-cell lymphomas 9.6
47 retinitis 9.6
48 cataract 9.6
49 craniopharyngioma 9.6
50 amelanotic melanoma 9.6

Graphical network of the top 20 diseases related to Ocular Melanoma:



Diseases related to Ocular Melanoma

Symptoms & Phenotypes for Ocular Melanoma

MGI Mouse Phenotypes related to Ocular Melanoma:

43
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 9.91 IL2 KIT BAP1 MC1R BRCA2 SERPINF1
2 endocrine/exocrine gland MP:0005379 9.88 IL2 KIT BAP1 SERPINF1 BRCA2 CIITA
3 immune system MP:0005387 9.87 IL2 KIT BAP1 MC1R BRCA2 SERPINF1
4 digestive/alimentary MP:0005381 9.83 IL2 KIT BAP1 SERPINF1 BRCA2
5 neoplasm MP:0002006 9.65 IL2 KIT BAP1 MC1R BRCA2
6 no phenotypic analysis MP:0003012 9.46 IL2 KIT BAP1 MC1R
7 pigmentation MP:0001186 9.13 KIT MC1R SERPINF1
8 reproductive system MP:0005389 9.02 IL2 KIT BAP1 SERPINF1 BRCA2

Drugs & Therapeutics for Ocular Melanoma

Drugs for Ocular Melanoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 92)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dacarbazine Approved, Investigational Phase 3,Phase 2 4342-03-4 5351166
2
Bevacizumab Approved, Investigational Phase 3,Phase 2 216974-75-3
3
Melphalan Approved Phase 3,Phase 2 148-82-3 460612 4053
4
Pembrolizumab Approved Phase 3,Phase 2,Phase 1 1374853-91-4
5
Imidazole Experimental, Investigational Phase 3,Phase 2 288-32-4 795
6
Fotemustine Experimental, Investigational Phase 3
7 Alkylating Agents Phase 3,Phase 2,Phase 1
8 Angiogenesis Inhibitors Phase 3,Phase 2
9 Angiogenesis Modulating Agents Phase 3,Phase 2
10 Immunosuppressive Agents Phase 3,Phase 2,Phase 1
11 Vaccines Phase 3,Phase 2
12 Antibodies, Monoclonal Phase 3,Phase 2,Phase 1
13 Immunoglobulins Phase 3,Phase 2,Phase 1
14 Antibodies Phase 3,Phase 2,Phase 1
15 Liver Extracts Phase 3,Phase 2,Phase 1
16 Mitogens Phase 3
17 Endothelial Growth Factors Phase 3
18
Cisplatin Approved Phase 2 15663-27-1 2767 441203 84093
19
Tamoxifen Approved Phase 2 10540-29-1 2733526
20
Gemcitabine Approved Phase 2 95058-81-4 60750
21
Temozolomide Approved, Investigational Phase 2 85622-93-1 5394
22
Sunitinib Approved, Investigational Phase 2 341031-54-7, 557795-19-4 5329102
23
Paclitaxel Approved, Vet_approved Phase 2 33069-62-4 36314
24
Carboplatin Approved Phase 2 41575-94-4 10339178 38904 498142
25
Cyclophosphamide Approved, Investigational Phase 2,Phase 1 50-18-0, 6055-19-2 2907
26
Fludarabine Approved Phase 2 21679-14-1, 75607-67-9 30751
27
Sorafenib Approved, Investigational Phase 2,Phase 1 284461-73-0 216239 406563
28
Mesna Approved, Investigational Phase 2 3375-50-6 598
29
Lenalidomide Approved Phase 2 191732-72-6 216326
30
Aldesleukin Approved Phase 2 110942-02-4, 85898-30-2
31
Xylometazoline Approved, Investigational Phase 2 526-36-3 5709
32
Vorinostat Approved, Investigational Phase 2 149647-78-9 5311
33
Citric Acid Approved, Nutraceutical, Vet_approved Phase 2 77-92-9 311
34
Niacin Approved, Investigational, Nutraceutical Phase 2,Phase 1 59-67-6 938
35
Nicotinamide Approved, Investigational, Nutraceutical Phase 2,Phase 1 98-92-0 936
36
Folic Acid Approved, Nutraceutical, Vet_approved Phase 2,Phase 1 59-30-3 6037
37
Treosulfan Investigational Phase 2 299-75-2 9296
38
Entinostat Investigational Phase 2 209783-80-2
39 Selective Estrogen Receptor Modulators Phase 2
40 Hormone Antagonists Phase 2
41 Hormones Phase 2
42 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 2
43 Estrogen Antagonists Phase 2
44 Estrogen Receptor Modulators Phase 2
45 Estrogens Phase 2
46 Anti-Infective Agents Phase 2
47 Antimetabolites Phase 2
48 Antimetabolites, Antineoplastic Phase 2
49 Antineoplastic Agents, Hormonal Phase 2
50 Bone Density Conservation Agents Phase 2

Interventional clinical trials:

(show all 46)

# Name Status NCT ID Phase Drugs
1 Collaborative Ocular Melanoma Study (COMS) Unknown status NCT00000124 Phase 3
2 Percutaneous Hepatic Perfusion vs Best Alternative Care in Patients With Hepatic-dominant Ocular Melanoma Recruiting NCT02678572 Phase 3 Dacarbazine;Ipilimumab;Pembrolizumab
3 Prevention of Neovascular Glaucoma by Intravitreal Injections of Anti-VEGF in Patients Treated With Proton Therapy for a Large Choroidal Melanoma Not yet recruiting NCT03172299 Phase 3 Aflibercept Injection;False injection
4 Vaccine Therapy in Treating Patients With Melanoma of the Eye Terminated NCT00036816 Phase 3
5 Intravenous or Hepatic Arterial Infusion of Fotemustine in Treating Patients With Unresectable Liver Metastases From Eye Melanoma Terminated NCT00110123 Phase 3 fotemustine;isolated perfusion
6 Study of Metastatic Ocular Melanoma Unknown status NCT00168870 Phase 2 Gemcitabine;Treosulfan
7 Sunitinib, Tamoxifen, and Cisplatin in Treating Patients With High-Risk Ocular Melanoma Unknown status NCT00489944 Phase 2 cisplatin;sunitinib malate;tamoxifen citrate
8 Temozolomide and Bevacizumab in Treating Patients With Metastatic Melanoma of the Eye Unknown status NCT01217398 Phase 2 temozolomide
9 Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Ocular Melanoma Completed NCT01814046 Phase 2 Aldesleukin;Cyclophosphamide;Fludarabine
10 Lenalidomide (Revlimid) to Treat Advanced Ocular Melanoma Completed NCT00109005 Phase 2 Revlimid
11 THE IPI - Trial in Advanced Melanoma: Melanoma Patients With Advanced Disease Completed NCT01355120 Phase 2 Ipilimumab
12 A Phase II Study of Isolated Hepatic Perfusion (IHP) in Patients With Ocular Melanoma Completed NCT00062933 Phase 2
13 Cabozantinib-S-Malate Compared With Temozolomide or Dacarbazine in Treating Patients With Metastatic Melanoma of the Eye That Cannot Be Removed by Surgery Completed NCT01835145 Phase 2 Cabozantinib S-malate;Dacarbazine;Temozolomide
14 Vaccine Therapy in Treating Patients With Metastatic Melanoma of the Eye Completed NCT00020475 Phase 2 gp100 antigen;interleukin-2;MART-1 antigen;Montanide ISA-51
15 Pyrazoloacridine in Treating Patients With Metastatic Skin or Eye Melanoma Completed NCT00003802 Phase 2 pyrazoloacridine
16 Interferon Beta in Treating Patients With Metastatic Cutaneous Melanoma or Ocular Melanoma Completed NCT00085306 Phase 2
17 Temozolomide or Selumetinib in Treating Patients With Metastatic Melanoma of the Eye Completed NCT01143402 Phase 2 Dacarbazine;Selumetinib;Temozolomide
18 Cixutumumab in Treating Patients With Metastatic Melanoma of the Eye Completed NCT01413191 Phase 2
19 Sorafenib, Carboplatin, and Paclitaxel in Treating Patients With Stage IV Melanoma of the Eye Completed NCT00329641 Phase 2 carboplatin;paclitaxel;sorafenib tosylate
20 Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Metastatic Melanoma of the Eye That Cannot Be Removed By Surgery Completed NCT00738361 Phase 2 nab-paclitaxel
21 Taxoprexin® Treatment for Advanced Eye Melanoma Completed NCT00244816 Phase 2 Taxoprexin
22 Efficacy Study of Pembrolizumab With Entinostat to Treat Metastatic Melanoma of the Eye Recruiting NCT02697630 Phase 2 Pembrolizumab;Entinostat
23 Phase 1B/2 Study in Subjects With Small to Medium Primary Choroidal Melanoma Recruiting NCT03052127 Phase 1, Phase 2 Light-activated AU-011
24 Study With T-cel Receptor Gene Therapy in Metastatic Melanoma Recruiting NCT02654821 Phase 1, Phase 2
25 STA-9090(Ganetespib) in Metastatic Ocular Melanoma Active, not recruiting NCT01200238 Phase 2 STA-9090
26 Study Assessing Two Models of Hypofractionated Protontherapy on Large Choroidal Melanomas Active, not recruiting NCT02602756 Phase 2
27 SIR-Spheres® 90Y Microspheres Treatment of Uveal Melanoma Metastasized to Liver Active, not recruiting NCT01473004 Phase 2
28 Vorinostat in Treating Patients With Metastatic Melanoma of the Eye Suspended NCT01587352 Phase 2 Vorinostat
29 CDX-1401 and Poly-ICLC Vaccine Therapy With or Without CDX-301 in Treating Patients With Stage IIB-IV Melanoma Suspended NCT02129075 Phase 2
30 Imatinib in Adult Patients With Metastatic Ocular Melanoma Terminated NCT00421317 Phase 2 Imatinib
31 Lenalidomide, Sunitinib, and Cyclophosphamide in Treating Patients With Stage IV Eye Melanoma Terminated NCT00482911 Phase 2 cyclophosphamide;lenalidomide;sunitinib malate
32 A Phase Ib/II Study of AEB071 and MEK162 in Adult Patients With Metastatic Uveal Melanoma Terminated NCT01801358 Phase 1, Phase 2 AEB071;MEK162
33 Imatinib Mesylate And Cyclophosphamide In Metronomic Administration: Dose Escalation Study Of Imatinib Mesylate Completed NCT01046487 Phase 1 Imatinib mesylate, Cyclophosphamide (Dosing level 1 );Imatinib mesylate, Cyclophosphamide (Dosing level 2);Imatinib mesylate, Cyclophosphamide (Dosing level 3)
34 Study Of OX40 Agonist PF-04518600 Alone And In Combination With 4-1BB Agonist PF-05082566 Recruiting NCT02315066 Phase 1 PF-04518600;PF-04518600;PF-04518600 plus PF-05082566;PF-04518600 plus PF-05082566
35 Pembrolizumab and Stereotactic Radiosurgery for Melanoma or Non-Small Cell Lung Cancer Brain Metastases Recruiting NCT02858869 Phase 1
36 Sorafenib and Radioembolization With Sir-Spheres® for the Treatment of Metastatic Ocular Melanoma Active, not recruiting NCT01893099 Phase 1 Sorafenib
37 Combined PET/CT Imaging for the Early Detection of Ocular Melanoma Metastasis Compared to CT Scanning Alone Completed NCT00351728
38 Study of Tumor Samples in Patients Undergoing Radiation Therapy or Surgery For Primary Melanoma of the Eye Completed NCT00952939
39 Cytogenetic Study of Ocular Melanoma Recruiting NCT00344799
40 Optical Coherence Tomography of Retinal Abnormalities Associated With Choroidal Nevus, Choroidal Melanoma and Choroidal Melanoma Treated With Iodine-125 Brachytherapy Recruiting NCT00346372
41 The Role of Inflammation in Ocular Tumours Recruiting NCT02909517
42 5 Year Registry Study to Track Clinical Application of DecisionDx-UM Assay Results and Associated Patient Outcomes Active, not recruiting NCT02376920
43 Definity for Ultrasound of Intraocular Tumors Not yet recruiting NCT01930968
44 Expanded Access Study of Melphalan With Delcath CS-PHP System in Patients With Ocular/Cutaneous Melanoma Mets to Liver No longer available NCT01728051 Melphalan
45 Investigative Trial of Interferon Alpha-2b To Shrink Cancer of the Eye Withdrawn NCT00621439 Pegylated Interfon Alpha 2B;Placebo
46 Validation of a Molecular Prognostic Test for Eye Melanoma Withdrawn NCT00406120

Search NIH Clinical Center for Ocular Melanoma

Genetic Tests for Ocular Melanoma

Anatomical Context for Ocular Melanoma

MalaCards organs/tissues related to Ocular Melanoma:

38
Eye, Liver, Skin, Testes, Bone, Endothelial, Lung

Publications for Ocular Melanoma

Articles related to Ocular Melanoma:

(show top 50) (show all 334)
# Title Authors Year
1
Reproducibility of a Noninvasive System for Eye Positioning and Monitoring in Stereotactic Radiotherapy of Ocular Melanoma. ( 28168935 )
2017
2
Ocular melanoma-when you have seen one, you have not seen them all: a clinical outcome study from the Surveillance, Epidemiology and End Results (SEER) database (1973-2012). ( 28115829 )
2017
3
Comment on "Milham & Stetzer (2016) Tumor-specific frequencies and ocular melanoma." Electromag Biol Med http://dx.doi.org/10.1080/15368378.2016.1234390. ( 27715332 )
2017
4
Dynamic Contrast-Enhanced Magnetic Resonance Imaging of Ocular Melanoma as a Tool to Predict Metastatic Potential. ( 28448404 )
2017
5
Health-related quality of life during trans-arterial chemoembolization with drug-eluting beads loaded with doxorubicin (DEBDOX) for unresectable hepatic metastases from ocular melanoma. ( 28754534 )
2017
6
Dry Eye Syndrome After Proton Therapy of Ocular Melanomas. ( 28586953 )
2017
7
PRL-3/PTP4A3 phosphatase regulates integrin I^1 in adhesion structures during migration of human ocular melanoma cells. ( 28284838 )
2017
8
Head and neck melanoma (excluding ocular melanoma): United Kingdom National Multidisciplinary Guidelines. ( 27841141 )
2016
9
A case report of a patient with metastatic ocular melanoma who experienced a response to treatment with the BRAF inhibitor vemurafenib. ( 27520988 )
2016
10
Metastatic melanoma after 23a88years of primary ocular melanoma. ( 27881589 )
2016
11
Feasibility of Proton Beam Therapy for Ocular Melanoma Using a Novel 3D Treatment Planning Technique. ( 27084652 )
2016
12
Imaging of ocular melanoma metastasis. ( 27168029 )
2016
13
Investigating the dosimetric impact of seed location uncertainties in Collaborative Ocular Melanoma Study-based eye plaques. ( 27475484 )
2016
14
Metastatic Ocular Melanoma to the Liver Exhibits Infiltrative and Nodular Growth Patterns. ( 27476775 )
2016
15
EPIDEMIOLOGICAL ANALYSIS OF OCULAR MELANOMA IN UNIVERSITY CLINIC CENTER IN TUZLA, BOSNIA AND HERZEGOVINA. ( 27698609 )
2016
16
Tumor-specific frequencies and ocular melanoma. ( 27552371 )
2016
17
Overexpression of hepatocyte growth factor and an oncogenic CDK4 variant in mice alters corneal stroma morphology but does not lead to spontaneous ocular melanoma. ( 26731561 )
2016
18
The toll-like receptor 5 agonist entolimod suppresses hepatic metastases in a murine model of ocular melanoma via an NK cell-dependent mechanism. ( 26655090 )
2016
19
Diffusion-weighted magnetic resonance imaging for predicting and detecting the response of ocular melanoma to proton beam therapy: initial results. ( 25578783 )
2015
20
Low thyroid hormone levels improve survival in murine model for ocular melanoma. ( 25868390 )
2015
21
Metastatic Ocular Melanoma Presenting as a Heart-Compressing Mediastinal Mass. ( 26434443 )
2015
22
Dynamic contrast-enhanced MRI of ocular melanoma. ( 25714038 )
2015
23
Nationwide Incidence of Ocular Melanoma in South Korea by Using the National Cancer Registry Database (1999-2011). ( 26207308 )
2015
24
Heterogeneous dose calculations for Collaborative Ocular Melanoma Study eye plaques using actual seed configurations and Task Group Report 43 formalism. ( 25533415 )
2015
25
A challenging case of ocular melanoma. ( 26429178 )
2015
26
Ocular melanoma and the BAP1 hereditary cancer syndrome: implications for the dermatologist. ( 24697775 )
2014
27
Effects of defining realistic compositions of the ocular melanoma on proton therapy. ( 25599060 )
2014
28
Method for verifying the air kerma strength of I-125 plaques for the treatment of ocular melanoma. ( 25207419 )
2014
29
Evidence-based integration of selective internal radiation therapy into the management of ocular melanoma liver metastases. ( 25478778 )
2014
30
Progression of ocular melanoma metastasis to the liver: the 2012 Zimmerman lecture. ( 23392528 )
2013
31
TERT promoter mutations in ocular melanoma distinguish between conjunctival and uveal tumours. ( 23799844 )
2013
32
Combined surgical resection and radiofrequency ablation as treatment for metastatic ocular melanoma. ( 22766897 )
2013
33
The Collaborative Ocular Melanoma Study, mortality by therapeutic approach, age and tumor size. ( 24069782 )
2013
34
Ocular melanoma metastasizing to intra-abdominal lymph nodes. ( 23762736 )
2013
35
SECONDARY NEUTRON DOSES IN PROTON THERAPY TREATMENTS OF OCULAR MELANOMA AND CRANIOPHARYNGIOMA. ( 24222710 )
2013
36
Diffusion-weighted imaging of ocular melanoma. ( 23614974 )
2013
37
Isolated Hepatic Perfusion for Ocular Melanoma Metastasis: Registry Data Suggests a Survival Benefit. ( 24141377 )
2013
38
Left ventricular metastasis from ocular melanoma: a new, rare, and unusual pathway? ( 23816109 )
2013
39
Ocular melanoma: an overview of the current status. ( 23826405 )
2013
40
Solitary secondary malignant melanoma of clavicle two years after enuclation for ocular melanoma. ( 23424696 )
2013
41
Pretherapeutic laboratory findings, extent of metastasis and choice of treatment as prognostic markers in ocular melanoma- a single centre experience. ( 23057648 )
2013
42
Baker's Cyst on F-18 FDG PET/CT in a Patient with Ocular Melanoma. ( 23486655 )
2012
43
Survival and complications following I^ knife radiosurgery or enucleation for ocular melanoma: a 20-year experience. ( 22231777 )
2012
44
Protein kinase C inhibitor AEB071 targets ocular melanoma harboring GNAQ mutations via effects on the PKC/Erk1/2 and PKC/NF-I_B pathways. ( 22653968 )
2012
45
Ocular melanoma. ( 23960984 )
2012
46
Ocular melanoma and mammary mucinous carcinoma in an African lion. ( 23009723 )
2012
47
Ocular melanoma metastasis to the cervical spine. ( 22245271 )
2012
48
Ocular immune privilege and ocular melanoma: parallel universes or immunological plagiarism? ( 22707951 )
2012
49
Ocular melanoma: what's new? ( 22234256 )
2012
50
Germline BAP1 inactivation is preferentially associated with metastatic ocular melanoma and cutaneous-ocular melanoma families. ( 22545102 )
2012

Variations for Ocular Melanoma

Expression for Ocular Melanoma

Search GEO for disease gene expression data for Ocular Melanoma.

Pathways for Ocular Melanoma

Pathways related to Ocular Melanoma according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 11.65 CIITA IL2 KIT
2 11.3 BAP1 KIT
3 11.16 IL2 KIT
4 11.02 IL2 KIT
5 10.24 KIT MC1R

GO Terms for Ocular Melanoma

Biological processes related to Ocular Melanoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 negative regulation of inflammatory response GO:0050728 9.32 IL2 SERPINF1
2 hemopoiesis GO:0030097 9.26 BRCA2 KIT
3 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.16 IL2 KIT
4 pigmentation GO:0043473 8.96 KIT MC1R
5 T cell differentiation GO:0030217 8.62 IL2 KIT

Sources for Ocular Melanoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....